Possible cancer-causing capacity of COVID-19: is SARS-CoV-2 an oncogenic agent?
File(s)COVID and Cancer accepted version.docx (271.88 KB)
Accepted version
Author(s)
Jahankhani, Kasra
Ahangari, Fatemeh
Adcock, Ian M
Mortaz, Esmail
Type
Journal Article
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown diverse life-threatening effects, most of which are considered short-term. In addition to its short-term effects, which has claimed many millions of lives since 2019, the long-term complications of this virus are still under investigation. Similar to many oncogenic viruses, it has been hypothesized that SARS-CoV-2 employs various strategies to cause cancer in different organs. These include leveraging the renin angiotensin system, altering tumor suppressing pathways by means of its nonstructural proteins, and triggering inflammatory cascades by enhancing cytokine production in the form of a "cytokine storm" paving the way for the emergence of cancer stem cells in target organs. Since infection with SARS-CoV-2 occurs in several organs either directly or indirectly, it is expected that cancer stem cells may develop in multiple organs. Thus, we have reviewed the impact of coronavirus disease 2019 (COVID-19) on the vulnerability and susceptibility of specific organs to cancer development. It is important to note that the cancer-related effects of SARS-CoV-2 proposed in this article are based on the ability of the virus and its proteins to cause cancer but that the long-term consequences of this infection will only be illustrated in the long run.
Date Issued
2023-10
Date Acceptance
2023-05-22
Citation
Biochimie, 2023, 213, pp.130-138
ISSN
0300-9084
Publisher
Elsevier
Start Page
130
End Page
138
Journal / Book Title
Biochimie
Volume
213
Copyright Statement
Copyright © Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/37230238
PII: S0300-9084(23)00136-0
Subjects
Cancer
COVID-19
Oncogenesis
SARS-CoV-2
Publication Status
Published
Coverage Spatial
France
Date Publish Online
2023-05-23